| Identification | Back Directory | [Name]
3-Pyridinecarboxamide, 2-amino-N-(4-hydroxybicyclo[2.2.2]oct-1-yl)-5-[4-[(1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl]phenyl]- | [CAS]
2173389-57-4 | [Synonyms]
Zilurgisertib
Zilurgisertib (INCB-000928, NBU-928)
3-Pyridinecarboxamide, 2-amino-N-(4-hydroxybicyclo[2.2.2]oct-1-yl)-5-[4-[(1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hex-1-yl]phenyl]- | [Molecular Formula]
C30H38N4O3 | [MOL File]
2173389-57-4.mol | [Molecular Weight]
502.65 |
| Chemical Properties | Back Directory | [Boiling point ]
683.3±55.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.23±0.40(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Zilurgisertib (INCB-000928; NBU-928) is a selective ALK2 inhibitor with an IC50 value of 15 nM. Zilurgisertib inhibits SMAD1/5 phosphorylation with an IC50 value of 63 nM. Zilurgisertib inhibits hepcidin production and improve anemia. Zilurgisertib can be used in melanoma research[1][2]. | [in vivo]
Zilurgisertib can improve anemia in a mouse model of cancer-induced anemia, with increasing hemoglobin and red blood cell counts[2].
| [IC 50]
ALK2: 15 nM (IC50) | [References]
[1] Li J, et al. Preparation of aminopyridine derivatives and their use as selective ALK-2 inhibitors. WO2018014829 A1.
[2] Stubbs M C, et al. ALK2 and JAK2 inhibition for improved treatment of anemia in myelofibrosis patients: Preclinical profile of an ALK2 inhibitor Zilurgisertib in combination with Ruxolitinib. Blood, 2023, 142: 1789. |
|
| Company Name: |
ChemOrigin Pharm
|
| Tel: |
021-15026428026 15026428026 |
| Website: |
chemorigin.com/ |
|